Avalon GloboCare Corp. Stock News

Avalon GloboCare Corp. has announced the co-development of a novel, cell-free, in-silico system to facilitate its drug development efforts.

Image Provided by Pixabay Cytokine storm has made frequent appearances in the news lately as a life-threatening complication in patients suffering from COVID-19. The condition is an inflammatory syndr

FREEHOLD, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today an

Image Provided by Pexels With a compound annual growth rate (CAGR) of 34.2%, the global CAR-T cell therapy market is projected to hit $15.4 billion by 2028. This hypergrowth is largely driven by the i

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Hebei Senlan

PITTSBURGH, Aug. 04, 2021 (GLOBE NEWSWIRE) -- A new collaboration among UPMC Hillman Cancer Center, the University of Pittsburgh and New Jersey-based biotechnology company Avalon GloboCare Corp. (NASD

PITTSBURGH, Aug. 04, 2021 (GLOBE NEWSWIRE) -- A new collaboration among UPMC Hillman Cancer Center, the University of Pittsburgh and New Jersey-based biotechnology company Avalon GloboCare Corp. (NASD

Avalon GloboCare Corp, UPMC Hillman Cancer Center, and the University of Pittsburgh said they have forged a collaboration to develop new cancer immunotherapy approaches and streamline manufacturing pr

NEW YORK, July 16, 2021 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class

Avalon GloboCare Corp (NASDAQ:AVCO) said its planned acquisition target, SenlangBio, has initiated a first-in-human clinical trial evaluating anti-EphA2 chimeric antigen receptor (CAR) T-cell therapy

Avalon GloboCare Corp (NASDAQ:AVCO) told shareholders that its acquisition of Hebei Senlang Biotechnology Co Ltd, the largest cell therapy company in northern China in terms of biomanufacturing, clin

Previously Announced Execution of Definitive Agreement to Acquire SenlangBio

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Avalon GloboCare Corp. (NASDAQ: AVCO) and Hebei Senlang Biotechnology Co. Ltd is

Avalon GloboCare Corp (NASDAQ: AVCO) has agreed to acquire Hebei Senlang Biotechnology, dubbed SenlangBio, a China-based cell therapy company, in an all-stock transaction. In connection with the tr

Avalon GloboCare Corp (NASDAQ:AVCO) has reached a definitive agreement to acquire Hebei Senlang Biotechnology Co Ltd, the largest cell therapy company in northern China in terms of biomanufacturing sc